Nasal vaccine additive boosts flu survival in mice up to 100 days post-treatment

This research highlights a nasal vaccine additive that enhances flu survival in mice even 100 days after administration. The study addresses the challenge of protecting populations during the early stages of respiratory virus outbreaks, as seen during the COVID-19 pandemic. It explores the potential of temporarily strengthening the body's natural defenses without prior knowledge of the specific virus.

Originally published by gnews